You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Oxford Covid vaccine trial results due this year, chief investigator says

The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to be submitted for regulatory approval, along with Pfizer and BioNTech's candidate

Topics
Coronavirus Vaccine | Oxford University | Coronavirus

Reuters  |  London 

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
A vaccine that works is seen as a game-changer in the battle against the novel coronavirus

The Covid-19 vaccine developed by the University of Oxford could present late-stage trial results before the year end but it is unclear if it will be rolled out before Christmas, the chief trial investigator for the vaccine said on Wednesday.

"I'm optimistic that we could reach that point before the end of this year," Oxford Vaccine Trial Chief Investigator Andrew Pollard said of presenting trial results this year.

Pollard said working out whether or not the vaccine worked would likely come this year he said, after which the data would have to be carefully reviewed by regulators and then a political decision made on who should get the vaccine.

"Our bit - we are getting closer to but we are not there yet," Pollard, director of the Oxford Vaccine Group, said.

Asked if he expected the vaccine would start to be deployed before Christmas, he said: "There is a small chance of that being possible but I just don't know."

"Our trials are only one of many that are going on around the world, a number of which may well report before the end of the year, and so those steps will need to be happening for multiple different products," he said.

The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to be submitted for regulatory approval, along with Pfizer and BioNTech's candidate.

A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.2 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people.

If it works, a vaccine would allow the world to return to some measure of normality after the tumult of the pandemic.

Pollard said the U.S. Food and Drug Administration had set the bar for a vaccine being at least 50% effective - a level that would have a transformative impact on the pandemic.

"But to be able scientifically able to test 50% is a lot harder - you need a lot more cases to occur in the trials," he said. "So I think we are all hoping the vaccine will be more effective than that which means we will have an answer sooner."

"What the actual level of efficacy is unknown at the moment - no one has unblinded their trials and looked at the data so far."

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 04 2020. 16:39 IST
RECOMMENDED FOR YOU